Monoclonal anti-EGFreceptor antibody (ior-R3) pharmacokinetic study in tumor bearing nude mice: Role of the receptor-mediated endocytosis on drug clearance

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 27, Issue 2, 2002, Pages 101-105

  Duconge, Jorge ^a   Fernandez Sanchez E ^b   Macias, A ^b   Castillo, R ^b   Garcia, I ^b   Beausoleiu, I ^b   Amador, J F ^b   Matheu, J ^b  

^a UNIVERSITY OF HAVANA   (Cuba)

^b CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

Clearance (CL); Epidermal growth factor receptor (EGFr); Monoclonal Antibody (MAb) ior R3; Pharmacokinetics (PK); Receptor mediated endocytosis (RME); Tumor bearing mice

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BOLUS INJECTION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISPOSITION; ENDOCYTOSIS; HUMAN; HUMAN CELL; LUNG CANCER; MOUSE; NONHUMAN; NUDE MOUSE; TUMOR XENOGRAFT; ANIMAL; BLOOD; CELL CULTURE; DRUG SCREENING; MALE; METABOLISM; METHODOLOGY; PHYSIOLOGY;

ANIMAL; ANTIBODIES, MONOCLONAL; ENDOCYTOSIS; HUMAN; MALE; MICE; MICE, NUDE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SUPPORT, NON-U.S. GOV'T; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS; ANIMALS; HUMANS;

EID: 0035987064     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03190423     Document Type: Article

References (12)

1. Statistical criteria for selecting a pharmacokinetic model
2. The dependence of the endocytosis of the EGFr on degree of receptor occupancy
3. Generación y caracterización primaria de anticuerpos monoclonales contra el receptor del factor de crecimiento epidérmico
4. Changes in protein and mRNA levels of EGF receptors in rat livers after administration of phenobarbitone or methylclofenapate
5. Can animal models be use to explored pharmacodynamics problems of clinical interest?
6. The case for preclinical pharmacodynamics
7. Induction of apoptosis and cell cycle by CP 358-774, an inhibitor of EGF receptor tyrosine kinase
8. Endocytosis of lisosomal targeting of EGFr are mediated by distinct sequences independent of the tyrosine kinase domains
9. Innovation that influence the pharmacology of monoclonal antibody guided tumour targetting
10. Cell surface binding and cellular internalization properties of suramin, a novel antineoplastic agent
11. Monoclonal anti- egfr (iior r3) antibody's pharmacokinetic studies on nude mice: A radio receptor analysis applied to serum drug quanntification